leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...7172737475767778798081...235236»
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
    Enrollment closed, Trial completion date, Trial primary completion date:  DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) -  Nov 14, 2022   
    P3,  N=560, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=100 --> 68 Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Nov 2028 | Trial primary completion date: Dec 2022 --> Nov 2024
  • ||||||||||  leucovorin calcium / Generic mfg.
    Review, Journal:  Vitamin requirements during stem cell transplantation: a systematic review. (Pubmed Central) -  Nov 10, 2022   
    Studies with paediatric patients or those that looked at vitamin derivates such as folinic acid were excluded...It is unclear if supplementation is needed during SCT, though assessing vitamin D levels prior to transplant should be considered. Further large observational studies or randomised control trials are required to establish vitamin requirements and guide supplementation protocols during SCT.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. (Pubmed Central) -  Nov 10, 2022   
    These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.
  • ||||||||||  Trial initiation date:  TRIPP-FFX: FOLFIRINOX Versus OncoSil (clinicaltrials.gov) -  Nov 9, 2022   
    P2,  N=80, Not yet recruiting, 
    Findings support investigation of drug combinations and novel dosages to reverse resistance and improve safety. Initiation date: Aug 2022 --> Jan 2023
  • ||||||||||  Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen
    COMPOSE: Pivotal Phase III Trial for WellDifferentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care () -  Nov 8, 2022 - Abstract #NANETS2022NANETS_132;    
    P3
    There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and cytoreductive procedures...More sites and countries will follow. CONCLUSIONS COMPOSE results are expected to inform about optimal treatment options for patients with well‑differentiated aggressive grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy.
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal:  Examination of the Effect of Proton Pump Inhibitors on the Anticancer Activity of Oxaliplatin. (Pubmed Central) -  Nov 8, 2022   
    CONCLUSIONS COMPOSE results are expected to inform about optimal treatment options for patients with well‑differentiated aggressive grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy. Even if L-OHP interacts with PPIs, clinical doses of PPIs were considered to have minimal effect on the antitumor effect of L-OHP.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Christmas Tree-Shaped Microneedles as FOLFIRINOX Spatiotemporal Delivery System for Pancreatic Cancer Treatment. (Pubmed Central) -  Nov 8, 2022   
    The multilayer structure imparts the MNs with enhanced adhesive ability and spatiotemporal drug release property, contributing to the antitumor effect on PC organoid models. Therefore, our Christmas tree-shaped MN patch represents an innovative approach for spatiotemporal multiple-drug delivering and realizes the combination chemotherapy for PC in a single platform.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Mixed Acinar-Neuroendocrine Pancreatic Carcinoma (MANEC): a Rare Subtype of Pancreatic Cancer (Coastal 1-5) -  Nov 7, 2022 - Abstract #APAPancreatic2022APA_Pancreatic_259;    
    MANEC is a subtype of MiNENs exhibiting characteristics of both acinar and neuroendocrine carcinoma, with a 0.2% reported incidence. The endocrine cells in MANEC tumors are usually non-functional and lack hormone synthesis, making an endocrine syndrome an unlikely presentation.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Trial completion date, Trial primary completion date:  Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy (clinicaltrials.gov) -  Nov 7, 2022   
    P=N/A,  N=50, Recruiting, 
    The endocrine cells in MANEC tumors are usually non-functional and lack hormone synthesis, making an endocrine syndrome an unlikely presentation. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
  • ||||||||||  Biomarker, Retrospective data, Journal:  CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. (Pubmed Central) -  Nov 5, 2022   
    FOLFOXIRI had a higher efficacy and higher conversion rate to secondary resection over the doublet regimen as an upfront treatment option, coupled with a manageable adverse event, but failed to improve the survival outcomes. CA19-9 values 4 months after commencing treatment are a significant prognostic factor in LAPC patients undergoing chemotherapy.
  • ||||||||||  methotrexate IV / Generic mfg.
    Safety of Novel Inpatient High Dose Methotrexate Protocol with Reduced Length of Hospital Stay (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_3105;    
    Our date suggests that patients who received high dose methotrexate can be safely discharged early if they exhibit normal drug clearance kinetics with in the first 48 hours after infusion, maintain normal renal function and continue oral hydration and leucovorin as outpatient. Adopting this protocol may have an economic benefit by shortening the length of hospitalization by 1-2 days.
  • ||||||||||  lunresertib (RP-6306) / Repare Therap
    New P2 trial:  RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) -  Nov 4, 2022   
    P2,  N=78, Not yet recruiting,